Drug intelligence / Profile preview

4-amino-n-[(2-sulfanylethyl)carbamoyl]benzenesulfonamide

Development stage: Unknown
Modality: Small Molecules

Overview

4-amino-n-[(2-sulfanylethyl)carbamoyl]benzenesulfonamide is a synthetic small molecule belonging to the sulfonamide class, specifically an aminobenzenesulfonamide derivative. Sulfonamides are known for their antimicrobial properties, though this compound is primarily listed as an experimental or research chemical and not as a marketed pharmaceutical. Its structure features a benzenesulfonamide moiety with an amine group at the para position and a carbamoyl group linked to a sulfanylethyl side chain. There is no evidence of clinical use or approval for any therapeutic indication, nor detailed information on its mechanism of action or biological targets[1][2][3][4].

Other names: 1-(4-aminobenzenesulfonyl)-3-(2-sulfanylethyl)urea

Beyond the preview

Go deeper on 4-amino-n-[(2-sulfanylethyl)carbamoyl]benzenesulfonamide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 4-amino-n-[(2-sulfanylethyl)carbamoyl]benzenesulfonamide.

Explore the full profile